Humacyte Inc (HUMA) Directors and Executive Officers

Officers & Directors

Diane Seimetz
Director

Gordon M. Binder
Director

Kathleen Sebelius
Director

Dale A. Sander
Chief Financial Officer, Chief Corporate Development Officer and Treasurer (Principal Financial and Accounting Officer)

Laura E. Niklason
President, Chief Executive Officer and Director (Principal Executive Officer)

C. Bruce Green
Director

Max Wallace
Director

Rajiv Shukla
Director

Brady W. Dougan
Director

Susan Windham-Bannister
Director

Michael T. Constantino
Director

Todd M. Pope
Director ,

Humacyte Inc currently has 184 employees.

News about Humacyte Inc Key Personnel

Humacytes Revolutionary Breakthrough: A Double-Edged Sword Amidst Financial Struggles

In a significant advancement for vascular medicine, Humacyte Inc. has secured FDA approval for its innovative product, SYMVESS, an acellular tissue-engineered vessel designed specifically to treat extremity vascular trauma. Heralded as a first-in-class bioengineered human tissue, SYMVESS is designed to be a universally implantable vascular conduit aimed at improving the outcomes of arterial replacement and repair procedures. The implications of this breakthrough are vast, potentially transforming treatment paradigms in both civilian and military healthcare settings where vascular injury is prevalent.The announcement follows the publication of compelling study results in JAMA Surgery, where Humacyte s Acellu...

Innovative Breakthrough: HAV's Vascular Trauma Treatment Gains FDA Priority Review, Surges Share Price

Human Acellular Vessel (HAV) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
BLA submission supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a Humanitarian Aid Program to treat wartime trauma injuries in Ukraine, this brings the share price to 41.22% in the past 90 days.
In a significant milestone for vascular trauma treatment, the Human Acellular Vessel (HAV) has been granted priority review by the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA). The HAV, a groundbreaking medical innovation developed to address the complex challenges of vascular trauma, has sho...